About us

2023-06-13

Announcement: Energenesis Biomedical has signed a Memorandum of Understanding (MOU) with Healiva SA, a company based in Switzerland, to establish a

We are excited to announce our collaboration with Healiva SA from Switzerland to expedite the entry of our ENERGI-F703 diabetic foot ulcer topical gel (referred to as F703 DFU) into the global market. Together, we will focus on the development and commercialization of F703 DFU in the Swiss and European markets, marking the beginning of a comprehensive partnership.

The key objectives of our collaboration with Healiva SA are as follows:

1. Our company plans to conduct Phase III clinical trials for F703 DFU in Europe.
2. Healiva SA intends to integrate our F703 DFU gel into their portfolio of wound healing products.
3. Both parties will work hand in hand to promote the development and commercialization of F703 DFU in the European market.
4. This Memorandum of Understanding expresses the willingness and consensus of both parties to collaborate and does not hold any binding legal obligations.

back